Secukinumab Provides Higher Symptomatic Improvement Versus Adalimumab in Psoriatic Arthritis- Comparative Effectiveness Up to 48 Weeks Assessed by two Matching-Adjusted indirect Comparisons
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2958
https://www.valueinhealthjournal.com/article/S1098-3015(17)33292-8/fulltext
Title :
Secukinumab Provides Higher Symptomatic Improvement Versus Adalimumab in Psoriatic Arthritis- Comparative Effectiveness Up to 48 Weeks Assessed by two Matching-Adjusted indirect Comparisons
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33292-8&doi=10.1016/j.jval.2017.08.2958
First page :
A935
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2707